Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7855)
All Articles published online
|
Publishing Process of This Article
|
Feb 14, 2015 (publication date) through Nov 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kawakami K, Inoue T, Murano M, Narabayashi K, Nouda S, Ishida K, Abe Y, Nogami K, Hida N, Yamagami H, Watanabe K, Umegaki E, Nakamura S, Arakawa T, Higuchi K. Effects of oral tacrolimus as a rapid induction therapy in ulcerative colitis. World J Gastroenterol 2015; 21(6): 1880-1886 [PMID: 25684955 DOI: 10.3748/wjg.v21.i6.1880] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i6/1880.htm |
| Number | Citing Articles |
| 1 |
Noritaka Takatsu, Takashi Hisabe, Masahiro Kishi, Teruyuki Takeda, Shigeyoshi Yasukawa, Akihiro Koga, Ken Kinjo, Fumihito Hirai, Toshiharu Ueki, Kenshi Yao. Thiopurine naivety at tacrolimus induction is a predictor of long‐term remission in patients with intractable ulcerative colitis who responded to tacrolimus. Journal of Gastroenterology and Hepatology 2023; 38(1): 52 doi: 10.1111/jgh.16006
|
| 2 |
Iago Rodríguez-Lago, Olga Merino, Óscar Nantes, Carmen Muñoz, Urko Aguirre, José Luis Cabriada. Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease. Revista Española de Enfermedades Digestivas 2016; 108 doi: 10.17235/reed.2016.4447/2016
|
| 3 |
Yujiro Henmi, Kazuki Kakimoto, Takuya Inoue, Kei Nakazawa, Minori Kubota, Azusa Hara, Takashi Mikami, Yutaka Naka, Yuki Hirata, Yoshimasa Hirata, Taisuke Sakanaka, Sadaharu Nouda, Toshihiko Okada, Ken Kawakami, Toshihisa Takeuchi, Kazunari Tominaga, Kazuhide Higuchi. Cytomegalovirus infection in ulcerative colitis assessed by quantitative polymerase chain reaction: risk factors and effects of immunosuppressants. Journal of Clinical Biochemistry and Nutrition 2018; 63(3): 246 doi: 10.3164/jcbn.18-14
|
| 4 |
Catherine O’Reilly, Susan Mills, Mary C. Rea, Aonghus Lavelle, Subrata Ghosh, Colin Hill, R. Paul Ross. Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches. Microbiome Research Reports 2023; 2(4) doi: 10.20517/mrr.2023.41
|
| 5 |
Iago Rodríguez‐Lago, Jesús Castro‐Poceiro, Agnès Fernández‐Clotet, Francisco Mesonero, Antonio López‐Sanromán, Alicia López‐García, Lucía Márquez, Ariadna Clos‐Parals, Fiorella Cañete, Miren Vicuña, Óscar Nantes, Olga Merino, Virginia Matallana, Jordi Gordillo, Ainara Elorza, Raquel Vicente, María José Casanova, Rocío Ferreiro‐Iglesias, Pablo Pérez‐Galindo, José Manuel Benítez, Carlos Taxonera, María José García, Eduardo Martín, Urko Aguirre, Javier P. Gisbert. Tacrolimus induces short‐term but not long‐term clinical response in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2020; 51(9): 870 doi: 10.1111/apt.15687
|
| 6 |
Keiichi Haga, Tomoyoshi Shibuya, Kei Nomura, Koki Okahara, Osamu Nomura, Dai Ishikawa, Naoto Sakamoto, Taro Osada, Akihito Nagahara. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. Journal of Clinical Medicine 2020; 9(6): 1771 doi: 10.3390/jcm9061771
|
| 7 |
Biyu Wu, Jinglu Tong, Zhihua Ran. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflammatory Bowel Diseases 2020; 26(1): 24 doi: 10.1093/ibd/izz068
|
| 8 |
Peter Hoffmann, Cyrill Wehling, Johannes Krisam, Jan Pfeiffenberger, Nina Belling, Annika Gauss. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World Journal of Gastroenterology 2019; 25(13): 1603-1617 doi: 10.3748/wjg.v25.i13.1603
|
| 9 |
Katsuyoshi Matsuoka, Eiko Saito, Toshimitsu Fujii, Kento Takenaka, Maiko Kimura, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe. Tacrolimus for the Treatment of Ulcerative Colitis. Intestinal Research 2015; 13(3): 219 doi: 10.5217/ir.2015.13.3.219
|
| 10 |
Joelynn Dailey, Jeffrey S. Hyams. Pediatric Inflammatory Bowel Disease. 2023; : 103 doi: 10.1007/978-3-031-14744-9_8
|
| 11 |
Mukta Gupta, Vijay Mishra, Monica Gulati, Bhupinder Kapoor, Amrinder Kaur, Reena Gupta, Murtaza M. Tambuwala. Natural compounds as safe therapeutic options for ulcerative colitis. Inflammopharmacology 2022; 30(2): 397 doi: 10.1007/s10787-022-00931-1
|
| 12 |
Yuichi Muraki, Shugo Mizuno, Kaname Nakatani, Hiroki Wakabayashi, Eiji� Ishikawa, Toshimitsu Araki, Akira Taniguchi, Shuji Isaji, Masahiro Okuda. Monitoring of peripheral blood cluster of differentiation 4+ adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases. Experimental and Therapeutic Medicine 2017; doi: 10.3892/etm.2017.5364
|
| 13 |
Sukrit Sud, Sanjeev Sachdeva, Amarender Singh Puri. Tacrolimus as rescue therapy for steroid-dependent/steroid-refractory ulcerative colitis: Experience from tertiary referral center in India. Indian Journal of Gastroenterology 2021; 40(6): 598 doi: 10.1007/s12664-021-01185-5
|
| 14 |
Juan LASA, Pablo OLIVERA. EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arquivos de Gastroenterologia 2017; 54(2): 167 doi: 10.1590/s0004-2803.201700000-15
|
| 15 |
Jing-Jing Wang, Yi-Hong Fan. Advances in research of tacrolimus for treatment of inflammatory bowel disease. World Chinese Journal of Digestology 2019; 27(13): 842 doi: 10.11569/wcjd.v27.i13.842
|
| 16 |
Dai Ishikawa, Takashi Sasaki, Taro Osada, Kyoko Kuwahara-Arai, Keiichi Haga, Tomoyoshi Shibuya, Keiichi Hiramatsu, Sumio Watanabe. Changes in Intestinal Microbiota Following Combination Therapy with Fecal Microbial Transplantation and Antibiotics for Ulcerative Colitis. Inflammatory Bowel Diseases 2017; 23(1): 116 doi: 10.1097/MIB.0000000000000975
|
| 17 |
Takayasu Suzuka, Takuya Kotani, Tohru Takeuchi, Youhei Fujiki, Kenichiro Hata, Shuzo Yoshida, Takeshi Shoda, Shigeki Makino, Shigeki Arawaka. Efficacy and safety of oral high‐trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. International Journal of Rheumatic Diseases 2019; 22(2): 303 doi: 10.1111/1756-185X.13414
|
| 18 |
K. J. Schmidt, N. Müller, A. Dignass, D. C. Baumgart, H. Lehnert, E. F. Stange, K. R. Herrlinger, K. Fellermann, J. Büning. Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues. Journal of Crohn's and Colitis 2016; 10(1): 31 doi: 10.1093/ecco-jcc/jjv175
|
| 19 |
Natsuki Ishida, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto. Early serum albumin changes in patients with ulcerative colitis treated with tacrolimus will predict clinical outcome. World Journal of Gastroenterology 2021; 27(22): 3109-3120 doi: 10.3748/wjg.v27.i22.3109
|
| 20 |
Yuto Yamada, Yuta Ohno, Takashi Niwa, Hiroko Kato‐Hayashi, Hideki Hayashi, Takashi Ibuka, Hiroshi Araki, Tadashi Sugiyama, Masahito Shimizu, Akio Suzuki. Rapid attainment of target trough concentrations of tacrolimus for early improvement of clinical symptoms in patients with ulcerative colitis. Journal of Clinical Pharmacy and Therapeutics 2019; 44(3): 409 doi: 10.1111/jcpt.12800
|
| 21 |
Yuga Komaki, Fukiko Komaki, Akio Ido, Atsushi Sakuraba. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2016; 10(4): 484 doi: 10.1093/ecco-jcc/jjv221
|
| 22 |
Calvin J. Meaney, Spinel Karas. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. Side Effects of Drugs Annual 2016; 38: 407 doi: 10.1016/bs.seda.2016.08.001
|
| 23 |
Hilal Ahmad, Vijay L. Kumar. Pharmacotherapy of ulcerative colitis – current status and emerging trends. Journal of Basic and Clinical Physiology and Pharmacology 2018; 29(6): 581 doi: 10.1515/jbcpp-2016-0014
|
| 24 |
Peter Townsend, Jeffrey S. Hyams. Pediatric Inflammatory Bowel Disease. 2017; : 95 doi: 10.1007/978-3-319-49215-5_8
|
| 25 |
George Salem, Kai Ding, Atsushi Sakuraba, Russell Cohen. Role of Topical Tacrolimus in the Management of Proctitis, Perianal Manifestations in Crohn's Disease, and Chronic Pouchitis: A Systematic Review. Journal of Investigative Medicine 2021; 69(4): 796 doi: 10.1136/jim-2020-001699
|
| 26 |
Martin Bürger, Carsten Schmidt, Niels Teich, Andreas Stallmach. Medical Therapy of Active Ulcerative Colitis. Visceral Medicine 2015; 31(4): 236 doi: 10.1159/000436959
|